ArticlePublic health challenges2024
How did states in the United States adapt their cancer control plan in response to the COVID-19 pandemic?
Article in Public health challenges, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The inclusion of tribes and American Indian and Alaska Native People in State comprehensive cancer control plans.Cancer causes & control : CCC · 2025Article
- Differences in COVID-19 preventive behaviors among Black and White cancer survivors in North Carolina.Journal of cancer survivorship : research and practice · 2025Article
- How did states in the United States adapt their cancer control plan in response to the COVID-19 pandemic?Public health challenges · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic upended the delivery of cancer services across the care continuum. By outlining specific strategies for addressing cancer in the state, cancer control plans serve a critical role during a public health emergency. This policy analysis aims to understand how states updated their cancer control plan as a response to COVID-19. All plans from 50 states and the District of Columbia were reviewed for language related to "COVID." Among the 51 cancer plans analyzed, 7 plans met the inclusion criteria (Illinois [IL], Iowa [IA], Maine [ME], Nevada [NV], North Carolina [NC], Utah [UT], and Vermont [VT]). These seven plans adapted their cancer control plan in response to the COVID-19 pandemic across three main themes: (1) improving care across the cancer care continuum, from prevention to screening and treatment; (2) improving cancer care service delivery by expanding telehealth, addressing workforce shortages, and investing in public health systems; and (3) achieving population health equity by addressing social determinants of health. Two states only adapted their plans by prioritizing future monitoring and evaluation activities as related to the COVID-19 pandemic (ME and VT). The other five states all took different approaches to improve cancer care by adapting their service delivery and addressing social determinants of health. IL prioritized access to cancer screenings through expanding equity informed telehealth models. IA also prioritized equitable screenings as well as clinical trial participation, by addressing workforce shortages. NV focused on prevention, leveraging telehealth and specifically targeted food security and job loss resulting from the pandemic. NC-directed cancer treatment efforts by addressing workforce shortages. UT integrated telehealth and equity initiatives to combat barriers like food insecurity and social disparities. Continued policy surveillance is needed to ensure that patients receive timely, appropriate cancer care during future public health emergencies. Research evaluating whether these plan adaptations improved outcomes or advanced equity remains warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.